Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Annals of Hematology
Published in: Annals of Hematology 9/2012

Open Access 01-09-2012 | Review Article

The challenge of individualised risk assessment and therapy planning in elderly high-risk myelodysplastic syndromes (MDS) patients

Author: Reinhard Stauder

Published in: Annals of Hematology | Issue 9/2012

Login to get access

Abstract

Myelodysplastic syndromes (MDS) represent one of the most frequent and serious haematologic diseases of the elderly. Effective therapies exist ranging from best supportive care to haematologic stem cell transplantation (HSCT). Decision making, however, is rather complex in this group of patients because ageing is a multidimensional process involving not only physiological changes but also changes in functional, social, emotional and cognitive capacities. All these factors can have a significant impact on the efficacy and tolerability of a potential therapy and therefore have to be thoroughly assessed before deciding on individual treatment regimens. Risk assessment tools are available both to classify the stage and prognosis of MDS and to meet the needs of elderly patients. A tool explicitly focussing on elderly MDS patients, however, is still missing. The current report approached this issue by combining the well established MDS-risk score ‘International Prognostic Scoring System’ (IPSS) with the ‘Multidimensional Geriatric Assessment’ (MGA). As decision making is most complex in high-risk MDS patients, the new algorithm is presented exemplarily for this group of patients. In a first step, MDS-related risk is identified using IPSS, in a second step, patients are assigned to one of three risk categories of the MGA (go-go/fit, slow-go/vulnerable, no-go/frail). While go-go patients might be subjected to therapies comparable to those given to younger patients, in no-go patients, a palliative therapy combined with best supportive care will probably be most appropriate. In slow-go patients, age-related life expectancy taken from public age statistics should be compared to the MDS-related life expectancy. Based on this combined assessment procedure and also on treatment tolerance in terms of the expectations/wishes of the patient and his/her family, an individualised therapeutic approach should be developed. Specific treatment recommendations for these three groups of patients are given, including HSCT, azanucleosides and best supportive care. To illustrate its practicability, i.e. the implementation of the novel algorithm in clinical practice, the case of an elderly high-risk MDS patient is presented and discussed in detail. This new algorithm will facilitate the identification of the very particular needs and conditions of elderly MDS patients in clinical practice. Based on this, individually tailored therapeutic approaches can be developed—the prerequisite for the best possible clinical outcome.
Literature
1.
Greenberg PL, Attar E, Bennett JM, Bloomfield CD, De Castro CM, Deeg HJ et al (2011) Myelodysplastic syndromes. J Natl Compr Canc Netw 9(1):30–56PubMed
2.
Germing U, Aul C, Niemeyer CM, Haas R, Bennett JM (2008) Epidemiology, classification and prognosis of adults and children with myelodysplastic syndromes. Ann Hematol 87(9):691–699PubMedCrossRef
3.
Balducci L, Extermann M (2000) Management of cancer in the older person: a practical approach. Oncologist 5(3):224–237PubMedCrossRef
4.
Balducci L (2007) Aging, frailty, and chemotherapy. Cancer Control 14(1):7–12PubMed
5.
Extermann M, Hurria A (2007) Comprehensive geriatric assessment for older patients with cancer. J Clin Oncol 10(14):1824–1831CrossRef
6.
Arking R (2006) The biology of aging: observations and principles, 3rd edn. Oxford University Press, New York
7.
Mahoney FI, Barthel DW (1965) Functional evaluation: the Barthel Index. Md State Med J 14:61–65PubMed
8.
Lawton MP, Brody EM (1969) Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist 9(3):179–186PubMedCrossRef
9.
Stauder R, Noesslinger TH, Pfeilstöcker M, Sperr WR, Wimazal F, Krieger O et al (2008) Impact of age and comorbidity in myelodysplastic syndromes. J Natl Compr Canc Netw 6(9):927–934PubMed
10.
Naqvi K, Garcia-Manero G, Sardesai S, Oh J, Vigil CE, Pierce S et al (2011) Association of comorbidities with overall survival in myelodysplastic syndrome: development of a prognostic model. J Clin Oncol 29(16):2240–2246PubMedCrossRef
11.
Inouye SK, Studenski S, Tinetti ME, Kuchel GA (2007) Geriatric syndromes: clinical, research, and policy implications of a core geriatric concept. J Am Geriatr Soc 55(5):780–791PubMedCrossRef
12.
Hurria A, Togawa K, Mohile SG, Owusu C, Klepin HD, Gross CP et al (2011) Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study. J Clin Oncol 29(25):3457–3465PubMedCrossRef
13.
Extermann M, Boler I, Reich RR, Lyman GH, Brown RH, Defelice J et al (2011) Predicting the risk of chemotherapy toxicity in older patients: the Chemotherapy Risk Assessment Scale for High-Age Patients (CRASH) score. Cancer. doi:10.​1002/​cncr.​26646
14.
Gosney M (2007) Contribution of the geriatrician to the management of cancer in older patients. Eur J Cancer 43(15):2153–2160PubMedCrossRef
15.
16.
Hutchins LF, Unger JM, Crowley JJ, Coltman CA Jr, Albain KS (1999) Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med 341(27):2061–2067PubMedCrossRef
17.
Extermann M, Albrand G, Chen H, Zanetta S, Schonwetter R, Zulian GB et al (2003) Are older French patients as willing as older American patients to undertake chemotherapy? J Clin Oncol 21(17):3214–3219PubMedCrossRef
18.
19.
Stauder R, Wimazal F, Nösslinger T, Krieger O, Sperr WR, Sill H et al (2008) Individualized management and therapy of myelodysplastic syndromes. Wien Klin Wochenschr 120(17–18):523–537PubMedCrossRef
20.
Deschler B, de Witte T, Mertelsmann R, Lübbert M (2006) Treatment decision-making for older patients with high-risk myelodysplastic syndrome or acute myeloid leukemia: problems and approaches. Haematologica 91(11):1513–1522PubMed
21.
Ria R, Moschetta M, Reale A, Mangialardi G, Castrovilli A, Vacca A et al (2009) Managing myelodysplastic symptoms in elderly patients. Clin Interv Aging 4:413–423PubMedCrossRef
22.
Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR et al (1982) Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 51(2):189–199PubMed
23.
Bruning RD, Orazi A, Germing U, Le Beau MM, Porwit A, Baumann I et al (2008) Myelodyspalstic syndromes. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW (eds) World Health Organization classification of tumours of the hematopoietic and lymphoid tissues, 4th edn. International Agency for Research on Cancer, Lyon
24.
Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G et al (1997) International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 89(6):2079–2088PubMed
25.
Malcovati L, Porta M, Pascutto C, Invernizzi R, Boni M, Travaglino E et al (2005) Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria, a basis for clinical decision making. J Clin Oncol 23(30):7594–7603PubMedCrossRef
26.
Sperr WR, Wimazal F, Kundi M, Baumgartner C, Nösslinger T, Makrai A et al (2010) Comorbidity as prognostic variable in MDS: comparative evaluation of the HCT-CI and CCI in a core dataset of 419 patients of the Austrian MDS Study Group. Ann Oncol 21(1):114–119PubMedCrossRef
27.
Valent P, Krieger O, Stauder R, Wimazal F, Nösslinger T, Sperr WR et al (2008) Iron overload in myelodysplastic syndromes (MDS)—diagnosis, management, and response criteria: a proposal of the Austrian MDS platform. Eur J Clin Invest 38(3):143–149PubMedCrossRef
28.
Giagounidis A, Leto di Priolo S, Ille S, Fenaux P (2011) A European survey on the detection and management of iron overload in transfusion-dependent patients with MDS. Ann Hematol 90(6):667–673PubMedCrossRef
29.
Nachtkamp K, Kündgen A, Strupp C, Giagounidis A, Kobbe G, Gattermann N et al (2009) Impact on survival of different treatments for myelodysplastic syndromes (MDS). Leuk Res 33(8):1024–1028PubMedCrossRef
30.
Parmara S, de Limaa M, Deegb HJ (2011) Champlin R Hematopoietic stem cell transplantation for myelodysplastic syndrome: a review. Semin Oncol 38(5):693–704CrossRef
31.
de Witte T (2011) Allogeneic stem cell transplantation for myelodysplastic syndromes: critical for cure? Clin Lymphoma Myeloma Leuk 11(Suppl 1):S46–S48PubMedCrossRef
32.
Deschler B, Binek K, Ihorst G, Marks R, Wäsch R, Bertz H et al (2010) Prognostic factor and quality of life analysis in 160 patients aged > or =60 years with hematologic neoplasias treated with allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 16(7):967–975PubMedCrossRef
33.
McClune BL, Weisdorf DJ, Pedersen TL, TunesdaSilva G, Tallman MS, Sierra J et al (2010) Effect of age on outcome of reduced-intensity hematopoietic cell transplantation for older patients with acute myeloid leukemia in first complete remission or with myelodysplastic syndrome. J Clin Oncol 28(11):1878–1887PubMedCrossRef
34.
Chevallier P, Szydlo RM, Blaise D, Tabrizi R, Michallet M, Uzunov M et al (2012) Reduced-intensity conditioning before allogeneic hematopoietic stem cell transplantation in patients over 60 years: a report from the SFGM-TC. Biol Blood Marrow Transplant 18(2):289–294PubMedCrossRef
35.
Bokhari SW, Watson L, Nagra S, Cook M, Byrne JL, Craddock C et al (2011) Role of HCT-comorbidity index, age and disease status at transplantation in predicting survival and non-relapse mortality in patients with myelodysplasia and leukemia undergoing reduced-intensity-conditioning hemopoeitic progenitor cell transplantation. Bone Marrow Transplant. doi:10.​1038/​bmt.​2011.​138
36.
Garcia-Manero G, Fenaux P (2011) Hypomethylating agents and other novel strategies in myelodysplastic syndromes. J Clin Oncol 29(5):516–523PubMedCrossRef
37.
38.
39.
40.
Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Finelli C, Giagounidis A et al (2009) Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 10(3):223–232PubMedCrossRef
41.
Seymour JF, Fenaux P, Silverman LR, Mufti GJ, Hellström-Lindberg E, Santini V et al (2010) Effects of azacitidine compared with conventional care regimens in elderly (≥75 years) patients with higher-risk myelodysplastic syndromes. Crit Rev Oncol Hematol 76(3):218–227PubMedCrossRef
42.
Fenaux P, Mufti GJ, Hellström-Lindberg E, Santini V, Gattermann N, Germing U et al (2010) Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. J Clin Oncol 28(4):562–569PubMedCrossRef
43.
Fenaux P, Gattermann N, Seymour JF, Hellström-Lindberg E, Mufti GJ, Duehrsen U et al (2010) Prolonged survival with improved tolerability in higher-risk myelodysplastic syndromes: azacitidine compared with low dose ara-C. Br J Haematol 149(2):244–249PubMedCrossRef
44.
Itzykson R, Thépot S, Quesnel B, Dreyfus E, Beyne-Ranzyl O, Turlure P et al (2011) Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine. Blood 117(2):403–411PubMedCrossRef
45.
Itzykson R, Thépot S, Achour B, Quesnel B, Dreyfus F, Turlure P, et al (2009) Azacytidine (AZA) in MDS (including RAEB-t and CMML) in patients (pts) ≥ 80 years: results of the French ATU Program. Blood 114: abstract 1773
46.
Fenaux P, Bowen D, Gattermann N, Hellström-Lindberg E, Hofmann WK, Pfeilstöcker M et al (2010) Practical use of azacitidine in higher-risk myelodysplastic syndromes: an expert panel opinion. Leuk Res 34(11):1410–1416PubMedCrossRef
47.
Seymour JF, Santini V, Fenaux P, Giagounidis AAN, Sanz GF, Finelli C, et al (2010) Achievement of red blood cell (RBC) transfusion independence with azacitidine (AZA) leads to improved survival in patients with higher-risk myelodysplasias regardless of baseline transfusion needs. Blood 116: abstract 1856
48.
Kornblith AB, Herndon JE 2nd, Silverman LR, Demakos EP, Odchimar-Reissig R, Holland JF et al (2002) Impact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: a cancer and leukemia group B study. J Clin Oncol 20(19):2441–2452PubMedCrossRef
49.
Santini V, Fenaux P, Mufti GJ, Hellström-Lindberg E, Silverman LR, List A et al (2010) Management and supportive care measures for adverse events in patients with myelodysplastic syndromes treated with azacitidine. Eur J Haematol 85(2):130–138PubMed
50.
Götze K, Platzbecker U, Giagounidis A, Haase D, Lübbert M, Aul C et al (2010) Azacitidine for treatment of patients with myelodysplastic syndromes (MDS): practical recommendations of the German MDS Study Group. Ann Hematol 89(9):841–850PubMedCrossRef
51.
Lübbert M, Suciu S, Baila L, Rüter BH, Platzbecker U, Giagounidis A et al (2011) Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: final results of the randomized phase III study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group. J Clin Oncol 29(15):1987–1996PubMedCrossRef
52.
Kantarjian HM, O’Brien S, Huang X, Garcia-Manero G, Ravandi F, Cortes J et al (2007) Survival advantage with decitabine versus intensive chemotherapy in patients with higher risk myelodysplastic syndrome: comparison with historical experience. Cancer 109(6):1133–1137PubMedCrossRef
53.
Kantarjian H, Issa JP, Rosenfeld CS, Bennett JM, Albitar M, DiPersio J et al (2006) Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer 106(8):1794–1803PubMedCrossRef
54.
Steensma DP, Baer MR, Slack JL, Buckstein R, Godley LA, Garcia-Manero G et al (2009) Multicenter study of decitabine administered daily for 5 days every 4 weeks to adults with myelodysplastic syndromes: the alternative dosing for outpatient treatment (ADOPT) trial. J Clin Oncol 27(23):3842–3848PubMedCrossRef
55.
Garcia-Manero G, Gore SD, Cogle C, Ward R, Shi T, Macbeth KJ et al (2011) Phase I study of oral azacitidine inmyelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia. J Clin Oncol 29(18):2521–2527PubMedCrossRef
56.
Adès L, Boehrer S, Prebet T, Beyne-Rauzy O, Legros L, Ravoet C et al (2009) Efficacy and safety of lenalidomide in intermediate-2 or high-risk myelodysplastic syndromes with 5q deletion: results of a phase 2 study. Blood 113(17):3947–3952PubMedCrossRef
57.
58.
59.
Kantarjian HM, Erba HP, Claxton D, Arellano M, Lyons RM, Kovascovics T, Gabrilove J, Craig M, Douer D, Maris M, Petersdorf S, Shami PJ, Yeager AM, Eckert S, Abichandani R, Faderl S (2010) Phase II study of clofarabine monotherapy in previously untreated older adults with acute myeloid leukemia and unfavorable prognostic factors. J Clin Oncol 28(4):549–555PubMedCrossRef
60.
Faderl S, Garcia-Manero G, Estrov Z, Ravandi F, Borthakur G, Cortes JE, O’Brien S, Gandhi V, Plunkett W, Byrd A, Kwari M, Kantarjian HM (2010) Oral clofarabine in the treatment of patients with higher-risk myelodysplastic syndrome. J Clin Oncol 28(16):2755–2760PubMedCrossRef
61.
Faderl S, Garcia-Manero G, Jabbour E, Ravandi F, Borthakur G, Estrov Z, Gandhi V, Byrd AL, Kwari M, Cortes J, Kantarjian HM (2012) A randomized study of 2 dose levels of intravenous clofarabine in the treatment of patients with higher-risk myelodysplastic syndrome. Cancer 118(3):722–728PubMedCrossRef
62.
Kantarjian H, Garcia-Manero G, O’Brien S, Faderl S, Ravandi F, Westwood R, Green SR, Chiao JH, Boone PA, Cortes J, Plunkett W (2010) Phase I clinical and pharmacokinetic study of oral sapacitabine in patients with acute leukemia and myelodysplastic syndrome. J Clin Oncol 28(2):285–291PubMedCrossRef
63.
Ravandi F, Faderl S, Cortes JE, Garcia-Manero G, Jabbour E, Boone PA, Kadia T, Borthakur G, Wierda WG, Wetzler M, Venugopal P, Chiao J, Kantarjian HM (2011) Phase 1/ 2 study of sapacitabine and decitabine administered sequentially in elderly patients with newly diagnosed AML. Blood (ASH Annual Meeting Abstracts), November, vol. 118, p. 3630
64.
Stauder R, Moser K, Holzner B, Sperner-Unterweger B, Kemmler G (2010) Six independent domains are defined by geriatric assessment in elderly cancer patients. Crit Rev Oncol Hematol 74:97–105PubMedCrossRef
65.
Valentiny C, Kemmler G, Stauder R (2012) Age, sex and gender impact multidimensional geriatric assessment in elderly cancer patients. J Geriatr Oncol 3:17–23CrossRef
66.
Tefferi A, Barosi G, Mesa RA, Cervantes F, Deeg HJ, Reilly JT et al (2006) International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT). Blood 108(5):1497–1503PubMedCrossRef
Metadata
Title
The challenge of individualised risk assessment and therapy planning in elderly high-risk myelodysplastic syndromes (MDS) patients
Author
Reinhard Stauder
Publication date
01-09-2012
Publisher
Springer-Verlag
Published in
Annals of Hematology / Issue 9/2012
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI
https://doi.org/10.1007/s00277-012-1472-8

Other articles of this Issue 9/2012

Annals of Hematology 9/2012 Go to the issue

Letter to the Editor

Nine years interval between first and second bone marrow transplantations and subsequent long-term survival—a case of acute myeloid leukemia with MLL-AF6 fusion gene

Original Article

Fine needle aspiration and core needle biopsy in the diagnosis of lymphadenopathy of unknown aetiology

Original Article

A national registry of haemoglobinopathies in Greece: Deducted demographics, trends in mortality and affected births

Letter to the Editor

Spontaneous remission after a year of romiplostim in an adult patient with refractory primary immune thrombocytopenia

Original Article

Increased yet iron-restricted erythropoiesis in postpartum mothers

Letter to the Editor

Langerhans/dendritic cell sarcoma arising from hairy cell leukemia: a rare phenomenon

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits